CeGaT

Research &
Pharma Solutions | TSO500

Analyze tumor samples using the TruSight™ Oncology 500 Assay

Every tumor is unique. Thus, it is essential to know and understand the underlying molecular pathology of a tumor to treat it properly. With comprehensive genomic profiling (CGP), hundreds of genes and cancer-relevant biomarkers can be analyzed simultaneously. The chances of discovering actionable alterations are increased by simultaneously assessing all these genes and biomarkers. With this approach, results might be available faster, and input material of biopsy samples can be saved. One possibility to comprehensively profile a tumor is the TruSight™ Oncology 500 Assay. With this assay, 523 cancer-relevant genes are analyzed for single nucleotide variants (SNVs), insertions and deletions (indels), and copy number variations (CNVs). Furthermore, the cancer-relevant biomarkers tumor mutational burden (TMB) and microsatellite instability (MSI) are assessed.

TMB measures the number of somatic mutations in a cancer patient's tumor and is quantified as mutations per megabase (mut/Mb). MSI indicates failures of the DNA mismatch repair system.

The application areas of TSO500 are manifold and include:

- Stratifying patients for the best treatment choice
- Identifying patients eligible for clinical trials
- Driving clinical research, especially in immune therapy

Want to Discover More?
We invite you to take a look at our website.
www.cegat.com/TSO500

Our Product Portfolio for TSO500

	TSO500	TSO500 ctDNA
Species	Human	
Sequencing panel	TruSight™ Oncology 500	TruSight™ Oncology 500 ctDNA
Number of analyzed genes	523	
Starting material	Fresh frozen tissue, FFPE tissue, high molecular weight DNA, or fragmented DNA (FFPE)	Whole blood (e.g., Streck® tubes), plasma, other body fluids, isolated nucleic acids
Sequencing platform	Illumina	
Included deliverables	Project report, FASTQ-, BAM-, VCF-, and TSV-files, TMB/MSI report	

About Us

CeGaT was founded in 2009 in Tübingen, Germany. Our scientists are specialized in next-generation sequencing (NGS) for genetic diagnostics, and we also provide a variety of sequencing services for research purposes and pharma solutions. Our sequencing service portfolio is complemented by analyses suited for microbiome, immunology, and translational oncology studies.

Our dedicated project management team of scientists and bio-informaticians works closely with you to develop the best strategy to realize your project. Depending on its scope, we select the most suitable library preparation and conditions on our sequencing platforms.

We would be pleased to provide you with our excellent service. Contact us today to start planning your next project.

DAkkS
Deutsche Akkreditierungsstelle
D-PL-13206-01-00

Accredited by DAkkS according to DIN EN ISO/IEC 17025:2018

CAP ACCREDITED
COLLEGE of AMERICAN PATHOLOGISTS

CLIA CERTIFIED ID: 99D2130225

CeGaT GmbH
Research & Pharma Solutions
Paul-Ehrlich-Str. 23
72076 Tübingen
Germany

Phone: +49 7071 56544-333
Fax: +49 7071 56544-56
Email: rps@cegat.com
Web: www.cegat.com/rps

2023/10